Drug Trial Radar · NCT06422936
Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Actual
Start
May 27, 2024
Primary completion
Dec 2026
Study completion Jun 2028
Sponsor
- Lead sponsor
- Highlight TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability, pharmacodynamics and preliminary efficacy of intra-lesional BO-112 in patients with resectable primary low and high risk basal cell carcinoma. * primary endpoint is composite visual and pathological response \[at surgery\] on patient level as assessed by central review * secondary endpoints are 1. Occurrence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation or death on patient level. 2. Pathological response \[at surgery\] on patient level assessed by the investigator and central review, respectively, and visual response \[during the study and at surgery\] on patient level assessed by the investigator and central review, respectively.
Conditions
- Basal Cell Carcinoma
Interventions
BO-112Drug
Noncoding double-stranded (ds) RNA based on polyinosinic-polycytidylic acid (Poly I:C), formulated with polyethylenimine (PEI) for intra-lesional injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Visual and Pathological ResponseTime frame: at surgery
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Soroka Medical Center
Beersheba, Israel
Rambam Medical Center
Haifa, Israel
Hadassah Ein Kerem Medical Center
Jerusalem, Israel
Kaplan Medical Center
Rehovot, Israel
Hospital Clínic Barcelona
Barcelona, Spain
Hospital de Basurto
Bilbao, Spain
Clínica Universitaria de Navarra (CUN)
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Complejo Asistencial Universitario de Salamanca
Salamanca, Spain
Instituto Valenciano de Oncología (IVO)
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.